Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Annals of Oncology.
Times cited: 28
Accuracy of clinical detection of INO in MS: Corroboration with quantitative infrared oculography.
Times cited: 35